A combination of plasma amyloid β (Aβ) and phosphorylated (p)-tau biomarkers effectively detected Aβ pathology in patients with early Alzheimer’s disease (AD).
Why this matters
Cerebrospinal fluid (CSF) and imaging biomarkers have been used to effectively detect Aβ and tau pathologies in AD. Detection of AD biomarkers in blood is difficult as their concentrations are low.
A cheap, accessible method of AD blood biomarker detection could facilitate widespread implementation in clinical trials and care.